Actively Recruiting
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Led by Regeneron Pharmaceuticals · Updated on 2026-03-18
231
Participants Needed
40
Research Sites
641 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
CONDITIONS
Official Title
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced NSCLC that is unresectable or metastatic as described in the protocol
- Willing to provide tumor tissue as described in the protocol
- Documented presence of MET alteration as described in the protocol
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function as described in the protocol
You will not qualify if you...
- Received treatment with an approved systemic therapy or participated in a study of an investigational agent or device within 2 weeks as described in the protocol
- Not recovered from acute toxicities from prior therapy with certain exceptions as described in the protocol
- Received radiation therapy or major surgery within 14 days as described in the protocol
- Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Uncontrolled infection as described in the protocol
- Other protocol defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 40 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Withdrawn
2
University of California Irvine Medical Center - Bldg 56, RT81, Rm 241
Orange, California, United States, 92868
Completed
3
Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
Completed
4
Moffitt Cancer Center - McKinley Drive
Tampa, Florida, United States, 33612
Actively Recruiting
5
University of Kentucky, Markey Cancer Center Clinical Research Organization
Lexington, Kentucky, United States, 40536
Withdrawn
6
DNU_Massachusetts General Hospital_DNU
Boston, Massachusetts, United States, 02114
Withdrawn
7
Dana Farber Harvard Cancer Center Consortium
Boston, Massachusetts, United States, 02215
Completed
8
Henry Ford Health System
Detroit, Michigan, United States, 48202
Withdrawn
9
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Withdrawn
10
NYU Cancer Institute
New York, New York, United States, 10016
Withdrawn
11
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Completed
12
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Completed
13
Duke Cancer Center
Durham, North Carolina, United States, 27710
Withdrawn
14
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Withdrawn
15
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Withdrawn
16
University of Pittsburgh UPMC - Clinical Research Services
Pittsburgh, Pennsylvania, United States, 15232
Completed
17
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States, 75235
Withdrawn
18
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
19
Centre Georges Francois Leclerc
Dijon, Bourgogne-Franche-Comté, France, 21034
Withdrawn
20
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, Bretange, France, 35033
Completed
21
Institut Bergonie
Bordeaux, New Aquitaine, France, 33076
Completed
22
Centre Francois Baclesse (CFB)
Caen, Normandy, France, 14076
Completed
23
Centre Hospitalier Universitaire de Grenoble
Grenoble, France, 38043
Completed
24
Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve
Montpellier, France, 34295
Completed
25
National Cancer Center
Gyeonggi-do, Gyeonggi-do, South Korea, 10408
Actively Recruiting
26
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
27
The Catholic University Of Korea St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea, 16247
Actively Recruiting
28
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
29
Haeundae Paik Hospital
Pusan, Gyeongsangnam-do, South Korea, 48108
Actively Recruiting
30
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea, 58128
Actively Recruiting
31
Gachon University Gil Medical Center
Incheon, Namdong-gu, South Korea, 21565
Actively Recruiting
32
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea, 28644
Actively Recruiting
33
Pusan National University Hospital
Busan, South Korea, 49241
Actively Recruiting
34
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
35
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
36
Seol St. Mary's Hospital
Seoul, South Korea, 06591
Completed
37
Boramae Medical Center
Seoul, South Korea, 07061
Actively Recruiting
38
Korea University Guro Hospital
Seoul, South Korea, 08308
Actively Recruiting
39
Seoul National University Hospital
Seoul, South Korea, 3080
Actively Recruiting
40
Severance Hospital
Seoul, South Korea, 3722
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here